2022-06-20T14:46:09-05:00 2021-09-24 910189318 MOSS ADAMS LLP 6565 AMERICAS PARKWAY NE STE 600 ALBUQUERQUE NM 87110 990 2020-09-26 850110669 LOVELACE BIOMEDICAL RESEARCH INSTITUTE LOVE 5053489361 2425 RIDGECREST DRIVE SE ALBUQUERQUE NM 87108 SHANNON TOMA CHIEF OPERATING OFFICER 5053489361 2022-06-20 1 SHANNON TOMA 999009999 PAMELA ALEXANDERSON P01218925 5058787200 2022-06-20 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z ROBERT W RUBIN 2425 RIDGECREST DRIVE SE ALBUQUERQUE NM 87108 89487296 0 X WWW.LOVELACEBIOMEDICAL.ORG X 1965 NM THE LOVELACE BIOMEDICAL RESEARCH INSTITUTE (LBRI) IS A PRIVATE, BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO IMPROVING PUBLIC HEALTH THROUGH RESEARCH ON THE PREVENTION, TREATMENT AND CURE OF DISEASES. LBRI IS COMMITTED TO CURING DISEASES THROUGH RESEARCH AIMED AT UNDERSTANDING THEIR CAUSES AND BIOLOGICAL MECHANISMS; ASSESSING AND ELIMINATING EXPOSURES TO RESPIRATORY, NEUROLOGICAL AND OTHER HEALTH HAZARDS; AND DEVELOPING IMPROVED THERAPEUTICS, VACCINES, AND DIAGNOSTICS. LBRI IS BASED IN ALBUQUERQUE, NEW MEXICO. 14 13 470 13 40654 37404 14011130 12922849 58650412 74903418 3640374 1371114 86499 58247 76388415 89255628 0 0 0 0 31278062 31978794 0 0 0 42910929 48383936 74188991 80362730 2199424 8892898 159558180 189542168 48830694 60247201 110727486 129294967 X THE LOVELACE BIOMEDICAL RESEARCH INSTITUTE (LBRI) IS A PRIVATE, BIOMEDICAL RESEARCH ORGANIZATION DEDICATED TO IMPROVING PUBLIC HEALTH THROUGH RESEARCH ON THE PREVENTION, DIAGNOSIS, TREATMENT AND CURE OF DISEASES. LBRI IS DEDICATED TO THE DISCOVERY AND ADVANCEMENT OF CLINICAL SOLUTIONS FOR PREVENTION, DIAGNOSIS, TREATMENT AND CURING DISEASES THROUGH RESEARCH. THE RESEARCH IS AIMED AT UNDERSTANDING THEIR CAUSES AND BIOLOGICAL MECHANISMS; ASSESSING AND ELIMINATING EXPOSURES TO RESPIRATORY, NEUROLOGICAL AND OTHER HEALTH HAZARDS; MENTAL ILLNESS; TRAUMATIC BRAIN INJURY AND OTHER BRAIN DISORDERS; AND DEVELOPING IMPROVED THERAPEUTICS, VACCINES, AND DIAGNOSTICS. LBRI IS BASED IN ALBUQUERQUE, NEW MEXICO. 0 0 61883368 74903418 MEDICAL RESEARCH AND EDUCATIONAL ACTIVITY IN THE AREAS OF BASIC BIOMEDICAL RESEARCH, HEALTH AND POPULATION STUDIES, INCLUDING RESPIRATORY DISEASES SUCH AS ASTHMA, COPD, ALLERGY AND TOXIC EFFECTS OF ENVIRONMENTAL FACTORS. ADDITIONAL AREAS INCLUDE NEUROLOGIC CONDITIONS SUCH AS TRAUMATIC BRAIN INJURY, ADDICTION AND PSYCHOPATHY. 61883368 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 147 0 1 470 1 1 1 0 0 0 0 0 0 0 0 0 0 0 X 14 13 0 0 1 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 NM X X SHANNON TOMA 5053489361 2425 RIDGECREST DRIVE SE ALBUQUERQUE NM 87108 ROBERT RUBIN PHD CEO, PRESIDENT, DIRECTOR 38.00 X X 863089 0 37382 JACKIE LOVELACE JOHNSON CHAIRPERSON OF THE BOARD 2.00 X X 0 0 0 JANE DELGADO DIR VICE CHAIR OF NOMINATING COMMITTEE 2.00 X X 0 0 0 CHRIS SPENCER CPA DIR CHAIR BUDGET & FINANCE COMMITTEE 2.00 X X 0 0 0 PAMELA SULLIVAN DIR CHAIR AUDIT & COMPENSATION COMMITTEE 2.00 X X 0 0 0 GREGORY DOWNEY MD DIRECTOR 2.00 X 0 0 0 J GRANT BURCHAM DIRECTOR 2.00 X 0 0 0 MAJOR GENERAL JOHN DOESBURG DIRECTOR 2.00 X 0 0 0 MELVIN TWIEST MD DIRECTOR 2.00 X 0 0 0 SARA EASTERSON-BOND DIRECTOR 2.00 X 0 0 0 TESS BURLESON DIRECTOR 2.00 X 0 0 0 RICHARD GILL PHD DIRECTOR 2.00 X 0 0 0 SANDRA CHAVEZ DIRECTOR 2.00 X 0 0 0 TERRY DUNLAY DIRECTOR 2.00 X 0 0 0 SHANNON TOMA TREASURER EXEC VP, COO/CFO 38.00 X 657749 0 38139 FRANCES FULPS-LAUR ASSISTANT SECRETARY 6.00 X 100127 0 19711 DAVID FLANDERS VP, HUMAN RESOURCES 40.00 X 270576 0 32180 JACOB MCDONALD VP, APPLIED SCIENCE 40.00 X 332734 0 41297 SCOTT THATCHER VP, FINANCE (THROUGH JAN 2021) 40.00 X 293253 0 38046 STEVEN BELINSKY VP ACADEMIC RESEARCH / SR. SCIENCE 40.00 X 370783 0 37825 KENT KIEHL EXECUTIVE SCIENCE OFFICER 40.00 X 346184 0 38167 ANDREW MAYER VP, INTERDISCIPLINARY SCIENCE 40.00 X 247160 0 38502 EDWARD BARRETT SR. DIRECTOR, PHARMACOLOGY 40.00 X 219961 0 35536 MELANIE DOYLE-EISELE SR. DIRECTOR, LIFE SCIENCES 40.00 X 209350 0 30575 3910966 0 387360 43 0 1 0 UNIVERSAL PROTECTION SERVICES LP 161 WASHINGTON STREET SUITE 600 CONSHOHOCKEN PA 19428 OUTSOURCED SECURITY SERVICES 363003 MOSS ADAMS LLP 6565 AMERICAS PARKWAY NE SUITE 600 ALBUQUERQUE NM 87110 ACCOUNTING AND TAX SERVICES 359197 AIT BIOSCIENCES LLC 7840 INNOVATION BLVD INDIANAPOLIS IN 46278 DATA ANALYSIS 228607 KPMG LLP PO BOX 120754 DEPT 0754 DALLAS TX 753120754 AUDIT SERVICES 182323 IDEXX DISTRIBUTION INC ONE IDEXX DRIVE WESTBROOK ME 04092 DATA ANALYSIS 182096 8 12227646 695203 12922849 BIOMEDICAL RESEARCH 541700 63199171 63199171 INTERCOMPANY REIMBURSE 900099 11704247 11704247 74903418 1550631 1550631 40654 40654 52151 50892 180776 1259 -180776 -179517 -179517 17593 17593 17593 89255628 74903418 40654 1388707 2635782 393600 2242182 18716984 17400722 1316262 1612240 91774 1520466 7268572 3604685 3663887 1745216 297502 1447714 304485 304485 933411 933411 62880 62880 55077 55077 7164758 5834880 1329878 144262 114174 30088 228012 177220 50792 3457180 2056325 1400855 7363432 5576316 1787116 159436 55137 104299 69309 53108 16201 813405 813405 5015780 4263575 752205 917138 699829 217309 RESEARCH SUPPLIES 20275099 20274976 123 BAD DEBT 51594 51594 1368678 937951 430727 80362730 61883368 18479362 0 35394 9080497 10735139 24186263 18922309 614208 74725 812306 1133309 141925251 61973703 79829677 79951548 44288108 76615977 -911216 1658337 2073767 159558180 189542168 10911237 13402742 14549917 24826671 21711203 20181329 1658337 1836459 48830694 60247201 X 110727486 129294967 110727486 129294967 159558180 189542168 8892898 9674583 0 X 0 1 X 1 1 1 X 65 52159 31 14011130 12922849 26986234 65 52159 31 14011130 12922849 26986234 26986234 1248480 1500113 1912832 1629091 1550631 7841147 31612 40654 72266 -188296 -147651 120643 54887 17593 -142824 34756823 167810726 0.77640 0.63970 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2017 AMOUNT: $ 4,698. 2018 AMOUNT: $ 120,643. 2019 AMOUNT: $ 27,144. 2020 AMOUNT: $ 17,593. HIGH WAGE TAX CREDIT - OTHER INCOME REBATES - TECHNOLOGY TAX CREDIT - CORPORATE ALLOCATION - BAD DEBT RECOVERY - 2019 AMOUNT: $ 27,743. LOSS ON JOINT VENTURES - 2016 AMOUNT: $ -188,296. 2017 AMOUNT: $ -152,349. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 62880 62880 80299850 80362730 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 194240 1069 5080 62880 263269 250000 250000 250000 250000 1000000 1500000 104544 1110455 1214999 103890479 33109585 70780894 647105 635537 11568 31906510 25416628 6489882 4266158 2811953 1454205 79951548 DEFERRED COMP 457(B) AND 457(F) 1836459 1836459 X PART X, LINE 2: LBRI IS AN ENTITY EXEMPT FROM FEDERAL INCOME TAXES ON RELATED INCOME UNDER SECTION 501(A) OF THE INTERNAL REVENUE CODE (IRC) OF 1986, AS AMENDED, AS AN ORGANIZATION DESCRIBED IN IRC SECTION 501(C)(3). FURTHER, LBRI, HAS BEEN CLASSIFIED AS AN ORGANIZATION THAT IS NOT A PRIVATE FOUNDATION UNDER IRC SECTION 509(A) AS DESCRIBED IN IRC SECTION 170(B)(1)(A)(VI), AND AS SUCH, CONTRIBUTIONS TO LBRI QUALIFY AS CHARITABLE CONTRIBUTIONS. HOWEVER, INCOME GENERATED FROM CERTAIN ACTIVITIES UNRELATED TO LBRI'S TAX-EXEMPT PURPOSE IS SUBJECT TO TAX AS UNRELATED BUSINESS INCOME UNDER IRC SECTION 511. AS OF SEPTEMBER 24, 2021 AND SEPTEMBER 25, 2020, THE COMPANY PERFORMED A REVIEW OF ITS MATERIAL TAX POSITIONS IN ACCORDANCE WITH RECOGNITION AND MEASUREMENT STANDARDS ESTABLISHED BY US GAAP. AS A RESULT OF THIS REVIEW, THE COMPANY CONCLUDED THAT LBRI HAD NO UNREPORTED INCOME DERIVED FROM UNRELATED BUSINESS ACTIVITIES AND NO ENTITY LEVEL TAX POSITIONS THAT WOULD NOT MEET THE MORE LIKELY THAN NOT THRESHOLD. THE COMPANY FILES TAX RETURNS AS PRESCRIBED BY THE TAX LAWS OF THE JURISDICTIONS IN WHICH IT OPERATES. IN THE NORMAL COURSE OF BUSINESS, THE COMPANY IS SUBJECT TO EXAMINATION BY FEDERAL, STATE, LOCAL, AND FOREIGN JURISDICTIONS, WHERE APPLICABLE. AS OF SEPTEMBER 24, 2021 AND SEPTEMBER 25, 2020, THE TAX YEARS THAT REMAIN SUBJECT TO EXAMINATION BY THE MAJOR TAX JURISDICTIONS UNDER THE STATUTE OF LIMITATIONS ARE FROM THE YEAR ENDED SEPTEMBER 28, 2018 AND FORWARD. THE COMPANY RECOGNIZES INTEREST ACCRUED RELATED TO UNRECOGNIZED TAX BENEFITS IN INTEREST EXPENSE AND PENALTIES IN OPERATING EXPENSES IN THE CONSOLIDATED STATEMENT OF ACTIVITES. THERE WERE NO SUCH INTEREST OR PENALTIES RECORDED FOR THE YEARS ENDED SEPTEMBER 24, 2021 OR SEPTEMBER 25, 2020. X 1 1 X X X 0 1 0 0 0 0 0 1 0 ROBERT RUBIN PHD CEO, PRESIDENT, DIRECTOR 802089 0 61000 0 0 0 27881 0 9501 0 900471 0 0 0 SHANNON TOMA TREASURER EXEC VP, COO/CFO 606749 0 51000 0 0 0 27881 0 10258 0 695888 0 0 0 STEVEN BELINSKY VP ACADEMIC RESEARCH / SR. SCIENCE 324783 0 46000 0 0 0 27881 0 9944 0 408608 0 0 0 KENT KIEHL EXECUTIVE SCIENCE OFFICER 345184 0 1000 0 0 0 27881 0 10286 0 384351 0 0 0 JACOB MCDONALD VP, APPLIED SCIENCE 281734 0 51000 0 0 0 27881 0 13416 0 374031 0 0 0 SCOTT THATCHER VP, FINANCE (THROUGH JAN 2021) 292253 0 1000 0 0 0 27881 0 10165 0 331299 0 0 0 DAVID FLANDERS VP, HUMAN RESOURCES 244576 0 26000 0 0 0 26483 0 5697 0 302756 0 0 0 ANDREW MAYER VP, INTERDISCIPLINARY SCIENCE 236160 0 11000 0 0 0 25148 0 13354 0 285662 0 0 0 EDWARD BARRETT SR. DIRECTOR, PHARMACOLOGY 218961 0 1000 0 0 0 22139 0 13397 0 255497 0 0 0 MELANIE DOYLE-EISELE SR. DIRECTOR, LIFE SCIENCES 197850 0 11500 0 0 0 20659 0 9916 0 239925 0 0 0 PART I, LINE 4B ROBERT RUBIN 457(F) PLAN - 2020 CONTRIBUTION IS $66,272. SINCE DR. RUBIN IS VESTED IN THE 457(F) PLAN, THE ENTIRE AMOUNT OF HIS 2020 457(F) PLAN CONTRIBUTION IS INCLUDED IN TAXABLE INCOME. PART I, LINE 7 BONUSES ARE AWARDED ANNUALLY. MANAGEMENT IS PROVIDED AN AMOUNT, APPROVED BY THE BOARD, TO PAY IN ANNUAL BONUS. BONUS PAYMENTS ARE REVIEWED AND APPROVED BY THE EMPLOYEE'S DIRECT SUPERVISOR, HEAD OF HUMAN RESOURCES, AND CEO. CEO BONUS IS ESTABLISHED BY THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS AND FURTHER APPROVED BY THE FULL BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 4 THE ORGANIZATION UPDATED ITS BYLAWS TO INCLUDE THE FOLLOWING CHANGES: 1. FISCAL YEAR OF THE CORPORATION SHALL END ON THE LAST FRIDAY IN SEPTEMBER. 2. SPECIFIES BOARD NUMBER BY STATING CORPORATION CURRENTLY HAS 15 DIRECTORS. THE BOARD SHALL AT ALL TIMES CONSIST OF NO FEWER THAN THREE DIRECTORS, OR ANY ODD NUMBER OF DIRECTORS NO GREATER THAN 25. 3. SPECIFIES BOARD TENURE BY STATING DIRECTORS SHALL ORDINARILY BE ELECTED TO A FOUR-YEAR TERM, BUT THE TERMS SHALL BE STAGGERED SO THAT THE TERMS OF APPROXIMATELY ONE QUARTER OF THE DIRECTORS SHALL EXPIRE AT EACH ANNUAL MEETING. 4. OUTLINES RESIGNATION/REMOVAL PROCEDURES OF BOARD MEMBERS DIRECTOR MAY RESIGN AT ANY TIME BY GIVING WRITTEN NOTICE OF SUCH RESIGNATION TO THE PRESIDENT AND SECRETARY OF THE CORPORATION. ANY DIRECTOR MAY BE REMOVED FROM OFFICE WITHOUT CAUSE BY THE AFFIRMATIVE VOTE OF TWO-THIRDS OF ALL THE DIRECTORS DURING A REGULAR OR SPECIAL MEETING. ANY TWO DIRECTORS MAY PROPOSE THE REMOVAL OF ANOTHER DIRECTOR BY WRITTEN NOTICE TO BOTH THE PRESIDENT AND SECRETARY OF THE CORPORATION. ANY DIRECTOR PROPOSED TO BE REMOVED SHALL BE ENTITLED TO AT LEAST FIVE DAYS NOTICE IN WRITING OF THE PROPOSED REMOVAL. 5. OUTLINES THE COMPOSITION AND RESPONSIBILITIES OF THE COMMITTEE THE COMMITTEE SHALL HAVE THE RESPONSIBILITY OF REVIEWING THE COMPENSATION OF SUCH SALARIED EMPLOYEES OF THE CORPORATION AS INDICATED BY THE BOARD FROM TIME TO TIME AND MAKING RECOMMENDATIONS THEREON TO THE BUDGET AND FINANCE COMMITTEE; AND SHALL MEET NOT LESS FREQUENTLY THAN ANNUALLY WITH THE CORPORATION'S INDEPENDENT PUBLIC ACCOUNTANTS TO REVIEW THE ANNUAL AUDIT OF THE CORPORATION AND SUCH OTHER MATTERS AS MAY BE BROUGHT TO THEM BY SUCH INDEPENDENT PUBLIC ACCOUNTANTS. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PRESENTED IN DRAFT FORM TO THE AUDIT AND COMPENSATION COMMITTEE AND TO THE FULL BOARD FOR REVIEW PRIOR TO SUBMISSION. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION HAS A CODE OF CONDUCT THAT ADDRESSES CONFLICTS OF INTEREST. IT IS PRESENTED TO THE BOARD ANNUALLY. ADDITIONALLY, ALL EMPLOYEES, INCLUDING OFFICERS, ARE REQUIRED TO READ AND ACKNOWLEDGE THE CODE ANNUALLY. IN ADDITION, IF A CONFLICT ARISES, THE CONFLICTED INDIVIDUAL RECUSES HIMSELF FROM VOTING ON THE ISSUE. FORM 990, PART VI, SECTION B, LINE 15 THE ORGANIZATION'S AUDIT AND COMPENSATION COMMITTEES RECEIVE COMPENSATORY RECOMMENDATION FROM HUMAN RESOURCES AND FROM MANAGEMENT AS TO: 1. PERCENT BASE SALARY INCREASE FOR THE ORGANIZATION AS A WHOLE WITH TARGETS AND THE DOLLAR AMOUNT OF IMPACT ARE PRESENTED TO AND APPROVED BY THE AUDIT AND COMPENSATION COMMITTEE. 2. TARGET AMOUNT OF BONUS COMPENSATION FOR THE ENTIRE ORGANIZATION AND THE DOLLAR IMPACT ARE PRESENTED AND APPROVED BY THE AUDIT AND COMPENSATION COMMITTEE. 3. CEO COMPENSATION (BASE, BONUS AND DEFERRED COMPENSATION) IS REVIEWED TO MARKET VALUE FOR SIMILAR POSITIONS IN THE INDUSTRY AND APPROVED BY THE AUDIT AND COMPENSATION COMMITTEE. THIS PROCESS IS DOCUMENTED AND WAS LAST COMPLETED IN OCTOBER 2021. FORM 990, PART VI, SECTION C, LINE 19 PROVIDED UPON REQUEST. LOVELACE SCIENTIFIC RESOURCES 2441 RIDGECREST DR SE ALBUQUERQUE NM 87108 850357767 CLINICAL TRIAL REASEARCH NM LOVELACE BIOMEDICAL RESEARCH INSTITUTE C 601552 46110 1.00000 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1 0 0 LOVELACE SCIENTIFIC RESOURCES Q 2495135 ACTUAL PAYMENT